绝经过渡期女性甲状腺功能减退与认知功能变化的关联:全国女性健康研究
本研究为多中心纵向研究,纳入2033名中年女性,其中227名(11.2%)为左甲状腺素(LT4)治疗的甲状腺功能减退者。基线时LT4治疗组处理速度和工作记忆评分较高,但随访期间两组认知下降速率无显著差异;即使TSH异常或控制练习效应后结果相似。
要点
- LT4治疗的甲状腺功能减退女性与无甲状腺疾病女性认知下降速率无显著差异。
- 基线时LT4治疗组处理速度评分56.5 vs 对照组54.4(P=0.006),工作记忆6.8 vs 6.4(P=0.018)。
- 甲状腺功能正常但有认知主诉的患者,临床医生应考虑甲状腺激素治疗不足以外的原因。
核心结论
- LT4治疗的甲状腺功能减退女性与无甲状腺疾病女性之间认知下降无差异。
- 对于年龄相仿且有认知主诉的患者,若甲状腺功能检测正常,临床医生应考虑甲状腺激素治疗不足以外的原因来解释这些症状。
研究设计与样本
- 多中心纵向研究,纳入美国7个入组点、代表5个种族/族裔群体的中年女性,来自全国女性健康研究。
- 共纳入2033名女性,其中227名(11.2%)符合LT4治疗的甲状腺功能减退标准,对照组为无甲状腺疾病女性。
- 每名参与者完成最多9次认知评估,测试处理速度、工作记忆和情景记忆(即时和延迟回忆)。
- 采用多变量广义线性混合模型分析各认知评估评分,以确定LT4治疗的甲状腺功能减退与认知功能轨迹的关联。
- 协变量包括社会人口学、临床特征和绝经状态(绝经前/早期围绝经、晚期围绝经、手术/绝经后);进行敏感性分析评估异常TSH水平和练习效应的影响。
主要发现
- 基线时,LT4治疗组处理速度平均评分56.5 vs 对照组54.4(P=0.006),工作记忆平均评分6.8 vs 对照组6.4(P=0.018),LT4治疗组均较高。
- 考虑LT4治疗的甲状腺功能减退随时间的影响时,无论是否调整协变量,甲状腺功能减退组与对照组在任何认知测量指标的下降速率上均无显著差异。
- 考虑TSH水平异常的LT4治疗女性或最小化练习效应后,结果相似。
临床怎么用
- 对于年龄相仿且有认知主诉的患者,若甲状腺功能检测正常,临床医生应考虑甲状腺激素治疗不足以外的原因来解释这些症状。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Patients treated for hypothyroidism with levothyroxine (LT4) monotherapy may present with persistent hypothyroidism symptoms, including cognitive symptoms, despite having a normal thyroid stimulating hormone (TSH) level. It remains unclear whether LT4 monotherapy is sufficient to normalize cognitive function outcomes over time. Methods: This is a multisite longitudinal study of a diverse group of women during midlife representing 5 ethnic/racial groups from 7 enrollment sites across the United States in the Study of Women's Health Across the Nation. Women were screened for a history of thyroid disease and the use of LT4. The study consisted of two primary groups: women with LT4-treated hypothyroidism and control women without thyroid disease. Each participant completed up to 9 cognitive assessments over the study period testing processing speed, working memory, and episodic memory (immediate and delayed recall). Multivariable generalized linear mixed models of scores for each cognitive assessment were developed to determine the association between LT4-treated hypothyroidism and cognitive function trajectories. Covariates included sociodemographic, clinical characteristics, and menopausal status (pre/early peri, late peri, and surgical/post). Sensitivity analyses were conducted to assess the impact of abnormal TSH levels and practice effects (i.e., improvements in scoring after repeated testing). Results: Of the 2033 women who were included in the study, 227 (11.2%) met criteria for LT4-treated hypothyroidism. At baseline, both processing speed and working memory scores were higher in LT4-treated women (mean processing speed scores: 56.5 vs 54.4; p value = 0.006; mean working memory scores: 6.8 vs 6.4; p value = 0.018). However, when considering the effect of LT4-treated hypothyroidism over time, there were no significant differences in the rate of cognitive decline (in any measure) between the hypothyroidism and control groups with or without covariate adjustment. The results were similar when considering LT4-treated women with abnormal TSH levels or after minimizing practice effects. Conclusions: We observed no difference in cognitive decline between women with LT4-treated hypothyroidism and women without thyroid disease. For similar aged patients with cognitive complaints, if thyroid function testing is normal, clinicians should consider causes other than inadequate thyroid hormone treatment to explain these symptoms.
引用
- Ettleson MD, Karavolos K, Burnett-Bowie SM, et al. The Association Between Hypothyroidism and Cognitive Function Change in Women across the Menopause Transition: The Study of Women's Health Across the Nation. Thyroid. 2024. PMID: 39225158. doi:10.1089/thy.2024.0358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。